Literature DB >> 1528712

Is Recormon less painful than Eprex after subcutaneous administration?

M W Hendriks1, F P Peters, P M Hooymans, T W Van de Wiel, D Janknegt, R Janknegt, J J Lohman.   

Abstract

In this study, we examined the differences in pain score after subcutaneous injection of the epoetin preparations Eprex and Recormon. Patients (n = 30) received 5 injections Eprex and 5 injections Recormon in a randomized double-blind sequence. 10 Min after receiving the injection the patient was asked to complete a visual and a verbal analogue scale and two descriptive scales. The results of 25 patients were used for statistical evaluation. The overall results indicate that there are significantly more patients reporting pain after subcutaneous injection of Eprex than after Recormon (11 versus 2 patients, p less than 0.05; McNemar test). 12 Patients reported no differences in pain. 43 Out of 123 injections Eprex and 69 out of 125 injections Recormon caused no pain (p less than 0.01; chi 2 9.455). For 4 patients Recormon was significantly (p less than 0.05) less painful than Eprex. It can be concluded that Recormon may be a less painful alternative for individual patients reporting pain after subcutaneous injection of Eprex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528712     DOI: 10.1007/bf01980483

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  5 in total

1.  [Pain measurement in clinical practice].

Authors:  A C Linssen; P Spinhoven
Journal:  Ned Tijdschr Geneeskd       Date:  1991-03-30

2.  Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.

Authors:  L A Frenken; H J van Lier; P G Gerlag; M den Hartog; R A Koene
Journal:  BMJ       Date:  1991-08-03

3.  X--Paired alternatives.

Authors:  T D Swinscow
Journal:  Br Med J       Date:  1976-07-24

Review 4.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 5.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

  5 in total
  4 in total

Review 1.  Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.

Authors:  R Whittington; L B Barradell; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 2.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 3.  Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.

Authors:  C J Dunn; A J Wagstaff
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 4.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.